### Alert
Watch for apnoeas and abdominal distension following administration. Lower concentration solutions and regimens minimising number of additional drops are recommended.

### Indication
Mydriatic (dilates the pupil) and cycloplegic (prevents accommodation of the eye) for ophthalmic examinations and therapeutic procedures.

### Action
Muscarinic acetylcholine receptor competitive antagonist. Prevents the accommodative muscle of the ciliary body and the sphincter muscle of the iris from responding to cholinergic stimulation.

### Drug Type
Antimuscarinic.

### Trade Name
Minims® Cyclopentolate hydrochloride.

### Presentation
Cyclopentolate hydrochloride 0.5% single-use preservative free eye drop, 0.5 mL per minim.

### Dosage/Interval
Cyclopentolate 0.5% is used in combination with phenylephrine 2.5% with or without tropicamide 0.5%. Suggested regimens are:

#### REGIMEN 1:
Phenylephrine 2.5% + cyclopentolate 0.5% + tropicamide 0.5% eye drops [1-4].
Instil one drop of each agent (5 minutes apart) into each eye 60 minutes prior to examination. Repeat if pupillary dilatation inadequate. Perform examination 60 to 120 minutes after instillation.

#### REGIMEN 2:
Phenylephrine 2.5% + cyclopentolate 0.5% eye drops [5].
Instil one drop of each agent (5 minutes apart) into each eye 60 minutes prior to examination. Repeat if pupillary dilatation inadequate. Perform examination 60 to 120 minutes after instillation.

Dark irides may require additional drops.

### Maximum daily dose
REGIMEN 1: 3 drops of each eye drop.
REGIMEN 2: 4 drops of each eye drop.

### Route
Topical instillation into the eyes from the minim or use a microdrop (5–7 microL) cannula.

### Preparation/Dilution
Not applicable.

### Administration
Apply pressure to the lacrimal sac during and for 60 seconds after instillation of eye drop to minimise systemic absorption. Wipe away excess medication. Consider withholding feeds for four hours from administration of the last drops to reduce incidence of feed intolerance.

### Monitoring
Heart rate and oxygen saturation in infants with bronchopulmonary dysplasia. Signs of ileus.

### Contraindications
Necrotising enterocolitis (NEC) at the time of eye examination.

### Precautions
Bronchopulmonary dysplasia – may increase absorption and decrease clearance.22,26 Severe neurological impairment – may increase risk of seizures. Feeding intolerance. Lower concentration solutions and regimens minimising number of additional drops are recommended to minimise toxicity.

### Drug Interactions
Not applicable.

### Adverse Reactions
Feeding intolerance, abdominal distension and increased gastric residuals. Apnoea, transient bradycardia (especially infants on respiratory support). Stinging or burning of eye. Tachycardia and increased blood pressure.
<table>
<thead>
<tr>
<th>Compatibility</th>
<th>Rarely, dry mouth, urinary retention, fever, vasodilatation, restlessness, agitation, seizures.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incompatibility</td>
<td>Phenylephrine, tropicamide, amethocaine</td>
</tr>
<tr>
<td>Stability</td>
<td>Discard unused portion immediately after use.</td>
</tr>
<tr>
<td>Storage</td>
<td>Store in refrigerator at 2°C to 8°C. Do not freeze. Protect from light.</td>
</tr>
<tr>
<td>Special Comments</td>
<td>Check correct strength of Minims® Cyclopentolate Eye Drops. Do NOT use 1% in neonates.</td>
</tr>
<tr>
<td>Evidence summary</td>
<td>Refer to full version.</td>
</tr>
<tr>
<td>References</td>
<td>Refer to full version.</td>
</tr>
</tbody>
</table>

**Original version Date:** 16/02/2018  
**Author:** NMF Consensus Group  
**Current Version number:** 1.0  
**Current Version Date:** 16/02/2018  
**Risk Rating:** Low  
**Due for Review:** 16/02/2023  
**Approval by:** JHCH CQ&PCC  
**Approval Date:** 24/07/2018

**Authors Contribution**  
- **Original author/s:** Michael Hewson, Cathy Langdon  
- **Expert review:** Mark Jacobs, Hughie Tsang, Kimberley Tan  
- **Evidence Review:** David Osborn  
- **Nursing Review:** Eszter Jozsa  
- **Pharmacy Review:** Jing Xiao, Mariella De Rosa, Cindy Chen  
- **Final content and editing review of the original:** Ian Whyte  
- **Electronic version:** Mariella De Rosa, Cindy Chen, Ian Callander  
- **Facilitator:** Srinivas Bolisetty